Level Up on Optimizing Treatment of DED: Pivotal Diagnostics (CME/CE Webcast)

Activity Description and Purpose

This educational activity is intended to help ophthalmologists and optometrists to optimize the treatment of patients with dry eye disease. Learners will focus on incorporating diagnostic strategies that examine meibomian gland function in routine practice and designing evidence-based treatment plans for patients with meibomian gland dysfunction–associated dry eye disease. The desired results of this activity are to cement clinicians’ knowledge of the role of evaporation in the pathogenesis of meibomian gland dysfunction and help them obtain practical strategies for screening, diagnosis, and effective treatment that can improve patient outcomes.

Target Audience

This educational activity is intended for ophthalmologists and optometrists.

Learning Objectives

After completing this activity, participants will be better able to:

  • Incorporate diagnostic strategies that lead to targeted treatment of dry eye disease
  • Review clinical evidence of approved treatments for dry eye disease
  • Design evidence-based treatment plans for patients with dry eye disease
Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 COPE
  • 0.50 Participation
Course opens: 
02/21/2024
Course expires: 
02/28/2025

Faculty

Kendall E. Donaldson, MD, MS
Professor of Clinical Ophthalmology
Medical Director
Bascom Palmer Eye Institute in Plantation
Plantation, Florida

Justin A. Schweitzer, OD, FAAO
Cataract, Cornea, Refractive, and Glaucoma Surgery Specialist
Vance Thompson Vision
Sioux Falls, South Dakota

Disclosure Policy

MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.

Faculty

Kendall E. Donaldson, MD, MS, is a consultant for AbbVie Inc, Alcon, Bausch & Lomb Incorporated, Dompé US, Inc, Johnson & Johnson Vision Care, Inc, LENSAR, LLC, Lumenis, Physician Recommended Nutriceuticals, ScienceBased Health, Tarsus Pharmaceuticals, Inc, and Zeiss.

Justin A. Schweitzer, OD, is a consultant for AbbVie Inc, Aerie Pharmaceuticals, Inc, Alcon, Astellas Pharma Inc, Avellino, Bausch & Lomb Incorporated, Dompé US, Inc, EyePoint Pharmaceuticals, Glaukos Corporation, Kala Pharmaceuticals, LKC Technologies, Inc, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Quidel Corporation, Reichert, Inc, RVL Pharmaceuticals, Inc, Sight Sciences, Sun Pharmaceutical Industries, Inc, Visus Therapeutics, and Zeiss; is on the speakers bureau for AbbVie Inc, Aerie Pharmaceuticals, Inc, Alcon, Bausch & Lomb Incorporated, Glaukos Corporation, LKC Technologies, Inc, Sight Sciences, Sun Pharmaceutical Industries, Inc, and Zeiss; and is an advisory board member of AbbVie Inc, Aerie Pharmaceuticals, Inc, Alcon, Astellas Pharma Inc, Avellino, Bausch & Lomb Incorporated, Dompé US Inc, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, Ocuphire Pharma, RVL Pharmaceuticals, Inc, ScienceBased Health, Sight Sciences, Visus Therapeutics, and Zeiss.

Peer Reviewer

This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.

Planners, Managers, and Writers

MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.

Accreditation Statement

MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

MedEdicus LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

COPE approved for 0.5 CE credit for optometrists.
COPE Course ID: 89588-TD (Asynchronous)
COPE Course Category: Treatment/Management of Ocular Disease

Administrator:

This activity, COPE Activity Number 127776, is accredited by COPE for continuing education for optometrists.

Disclosure of Commercial Support

MedEdicus has received commercial support from Bausch & Lomb Incorporated for this activity in the form of an unrestricted educational grant.

The content of this ACCME-/COPE-accredited CME/CE activity was planned and prepared independently by MedEdicus without input from members of an ineligible company.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Sponsored by

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.

Disclaimer

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, State University of New York College of Optometry, or Bausch & Lomb Incorporated.

This CME/CE activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 302.3b

Available Credit

  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 COPE
  • 0.50 Participation
Please login or register to take this course.

Clicking Register/Take course indicates that you have reviewed the CME/CE information for this activity.